SAMHD1 and acute myeloid leukemia: SAMHD1 has a deoxyribonucleoside (dNTP) triphosphohydrolase activity (19,20) essential for clinical response to dNTP analog therapeutic agents, including cytarabine and decitabine in acute myeloid leukemia (AML) (21–24).